BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) for BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HJRes 197 / SJRes 197, CRA related to the 2027 NBPP; HR 247 / S 46, Health Care Affordability Act; HR 6867 / S 3562, the NIH Clinical Trial Integrity Act; HR 3521 / S 4440, the Clinical Trial Modernization Act; HR 4710 / S 2420, No Surprises Act Enforcement Act; HR 5526 / S 1954, Biosimilar Red Tape Elimination Act; HR 5582 / S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8879 / S 4509, Patients Before Monopolies Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act; HR 9396, the Prior Authorization Accountability Act; HR 9397, the Premium Transparency Act; HR 9645, the Health Care Price Certainty for All Americans Act; HR 9661 / S 1414, the Expedited Access to Biosimilars Act; HR 10370, the AIM to Cure Kids with Cancer Act; HR 10788, the Lower Premiums, Faster Payments Act; S 976, the Insurance Fraud Accountability Act; S 1041, Affordable Prescriptions for Patients Act; S 1095, Stop STALLING Act; S 1096, Preserve Access to Affordable Generics & Biosimilars Act S 1097, Interagency Patent Coordination & Improvements Act; S 2658, Medication Affordability & Patent Integrity Act; S 3014, Ensuring Timely Access to Generics Act; S 3822, the Break Up Big Medicine Act Policies to address the expiration of the enhanced Advanced Premium Tax Credits; Policies to improve transparency in hospital and insurer costs and finances; Policies to streamline pediatric patient access to subspecialist care via telemedicine; Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance; Policies related to modernization of clinical trials; Policies related to the 2027 FDA user fee agreements; Implementation of the No Surprises Act; Policies related to oversight of insurance agents and brokers; Oversight and patient impact of the 340B program; Policies related to consolidation within the healthcare sector;
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE ANN BERGE | — |
| JESSICA BURNELL | — |
| BRIAN CONNELL | — |
| MATTHEW MARKS | — |
Medicare/Medicaid MMM
HR 3514 / S 1816, the Improving Seniors Timely Access to Care Act; HR 5243, a bill to increase data transparency for supplemental benefits under Medicare Advantage; HR 8375 / S 4384, the Medicare Advantage Improvement Act; HR 9392, Medicare Advantage Cost Transparency Act; S 1105, No UPCODE Act; S 1629, Same Care, Lower Cost Act; S 1936, Improving Access to Transfusion Care for Patients Act; S 4886, Medicare Cost Cap Act; CMS Interim Final Rule on Medicaid Work Requirements; Regulatory and legislative proposals to expand site-neutral payment in Medicare; Implementation of the Accelerating Kids Access to Care Act (HR 1509, S 752) Regulatory proposals related to most-favored nation drug pricing; Issues related to the cost of care, including consolidation and anti-competitive contracting
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE ANN BERGE | — |
| JESSICA BURNELL | — |
| BRIAN CONNELL | — |
| MATTHEW MARKS | — |
Budget/Appropriations BUD
HR 6500, the Continuing Appropriations and Extensions Act, 2027; HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research; HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research;
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN CONNELL | — |
| MATTHEW MARKS | — |
Medical/Disease Research/Clinical Labs MED
HR 6500, the Continuing Appropriations and Extensions Act, 2027; HR 7173, Follow the Science Act; HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research; HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research; HR 9632, Accelerating Innovation (AI) for Kids with Cancer Act; S 4494, American Cures Act; OMB Proposed Uniform Grants Regulation; Policies to enable international collaboration by NIH grantees; Policies to maintain the NIHs incremental grant funding model;
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE ANN BERGE | — |
| JESSICA BURNELL | — |
| BRIAN CONNELL | — |
| MATTHEW MARKS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.